Treatment with the PIKfyve inhibitor apilimod is able to induce cytotoxic effects in B-cell non-Hodgkin lymphoma and TFEB, the master transcriptional regulator of lysosomal biogenesis involved in a feedback loop with TRPML1 (58), regulates apilimod sensitivity (59). Here, PIKFYVE is linked to B-cell non-Hodgkin lymphoma.